Specify a stock or a cryptocurrency in the search bar to get a summary
Esperion Therapeutics Inc
ESPREsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
Analytics
WallStreet Target Price
8.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ESPR
Dividend Analytics ESPR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ESPR
Stock Valuation ESPR
Financials ESPR
Results | 2019 | Dynamics |